Nursing Elites

1. A male patient is concerned about the risk of prostate cancer while receiving finasteride (Proscar) for benign prostatic hyperplasia (BPH). What should the nurse explain about this risk?

• A. Finasteride has been shown to lower the risk of developing prostate cancer.
• B. Finasteride has no effect on the risk of developing prostate cancer.
• C. Finasteride may increase the risk of developing prostate cancer, so regular screening is important.
• D. Finasteride does not affect the risk of prostate cancer, so regular screening is unnecessary.

Correct answer: A

Rationale: The correct answer is A. Finasteride has been shown to lower the risk of developing prostate cancer. Studies have demonstrated that finasteride can reduce the incidence of prostate cancer. However, it is still recommended to have regular screening to monitor for any potential issues. Choice B is incorrect as finasteride has shown to have a positive effect on reducing prostate cancer risk. Choice C is inaccurate because finasteride decreases, not increases, the risk of prostate cancer. Choice D is incorrect as regular screening is still necessary despite the risk reduction associated with finasteride.

2. A 34-year-old woman has presented to the clinic for the first time, and the nurse learns that she has been taking Depo Provera for the past 13 years. This aspect of the woman's medical history should prompt what assessment?

• A. Cardiac stress testing
• B. Renal ultrasound
• C. Bone density testing
• D. Evaluation of triglyceride levels

Correct answer: C

Rationale: The correct answer is bone density testing (Choice C). Long-term use of Depo Provera, a hormonal contraceptive, is associated with decreased bone mineral density. Assessing bone density is crucial to monitor for potential osteoporosis. Cardiac stress testing (Choice A) is not indicated based on the medication history provided. Renal ultrasound (Choice B) and evaluation of triglyceride levels (Choice D) are not directly related to the use of Depo Provera.

3. A nurse is administering testosterone to a patient with hypogonadism. What outcome indicates that the treatment is having the desired effect?

• A. Increased libido
• B. Increased muscle mass
• C. Improved secondary sexual characteristics
• D. Decreased sperm count

Correct answer: C

Rationale: The correct answer is C: 'Improved secondary sexual characteristics.' Testosterone therapy in patients with hypogonadism typically leads to improved secondary sexual characteristics, which include increased muscle mass and libido. While increased libido (choice A) and increased muscle mass (choice B) are effects of testosterone therapy, they are more specific outcomes related to secondary sexual characteristics. Decreased sperm count (choice D) would not be an expected outcome of testosterone therapy for hypogonadism, as testosterone is essential for sperm production.

4. Which of the following birthmarks usually fade or regress as the child gets older?

• A. Hemangiomas
• B. Congenital dermal melanocytosis (i.e., Mongolian spots)
• C. Macular stains
• D. Hemangiomas, congenital dermal melanocytosis (i.e., Mongolian spots), and macular stains

Correct answer: D

Rationale: The correct answer is D. Hemangiomas, congenital dermal melanocytosis (i.e., Mongolian spots), and macular stains are birthmarks that usually fade or regress as the child gets older. Hemangiomas are vascular birthmarks that often shrink and fade over time. Congenital dermal melanocytosis (Mongolian spots) are blue-gray birthmarks commonly found on the lower back and buttocks of infants, which typically fade by adolescence. Macular stains, also known as salmon patches, are pink or red birthmarks that usually fade within the first few years of life. Choice D is correct because all the mentioned birthmarks tend to diminish as the child grows, unlike choices A, B, and C which do not fade or regress with age.

5. A woman suffers from amenorrhea. Which of the following medications will most likely be prescribed?

• A. Testosterone
• B. Follicle-stimulating hormone
• C. Estrogen
• D. Lactate

Correct answer: C

Rationale: Estrogen is the correct answer. Amenorrhea, the absence of menstruation, is often due to hormonal imbalances. Estrogen plays a crucial role in regulating the menstrual cycle. Prescribing estrogen can help address these hormonal imbalances and restore menstrual cycles. Testosterone (Choice A) is not typically prescribed for amenorrhea in women as it can further disrupt hormonal balance. Follicle-stimulating hormone (Choice B) is involved in stimulating ovulation and follicle development, not the primary treatment for amenorrhea. Lactate (Choice D) is not a medication used to treat amenorrhea.

Similar Questions